Lymphangioleiomyomatosis (LAM) Market Size

Lymphangioleiomyomatosis (LAM) Market size was over USD 128.91 million in 2023 and is anticipated to cross USD 237.13 million by 2036, growing at more than 4.8% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of lymphangioleiomyomatosis is estimated at USD 133.86 million.

Lymphangioleiomyomatosis (LAM) is a lethargic, progressive growth of smooth muscle cells all through the lungs, pulmonary blood vessels, lymphatics, and pleurae, leading to alteration of lung architecture, cystic emphysema, and progressive worsening of lung function. LAM is predominant in women, usually affecting those between 20 and 40 years. It is caused by mutations in the TSC1 or TSC2 genes, that are vital for the production of a protein known as hamartin and tuberin, responsible for destroying the tumors by preventing cells from growing and dividing in an uncontrolled way. Diagnosis is suspected based on symptoms and chest x-ray results and is confirmed by high-resolution CT, but the illness is slowly progressive and might often lead to respiratory failure and death in the future. Treatment might include consuming sirolimus or lung transplantation.